申请人:Pfizer Inc.
公开号:US04127665A1
公开(公告)日:1978-11-28
Novel spiro-thienohydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Preferred compounds include 6,7-dihydro-spiro-[benzo(b)thiophene-4(5H),4'-imidazolidine]-2',5'-dione, 2-chloro-spiro-[cyclopenta(b) thiophene-4,4'-imidazolidine]-2',5'-dione, spiro-[cyclopenta(c)thiophene-4,4'-imidazolidine]-2',5'-dione, 1-chloro-spiro[cyclopenta(c)thiophene-4,4'-imidazolidine]-2',5'-dione and 1,3-dichloro-spiro[cyclopenta(c)thiophene-4,4'-imidazolidine]-2',5'-dione.
本发明揭示了一种作为醛糖还原酶抑制剂和治疗慢性糖尿病并发症的治疗剂的新颖螺环噻唑醇衍生物。首选化合物包括6,7-二氢螺-[苯并(b)噻吩-4(5H),4'-咪唑烷]-2',5'-二酮、2-氯螺-[环戊(b)噻吩-4,4'-咪唑烷]-2',5'-二酮、螺-[环戊(c)噻吩-4,4'-咪唑烷]-2',5'-二酮、1-氯螺-[环戊(c)噻吩-4,4'-咪唑烷]-2',5'-二酮和1,3-二氯螺-[环戊(c)噻吩-4,4'-咪唑烷]-2',5'-二酮。